Vir Biotech Q2 net loss $194.8M; hep B/delta data on track for Q4

Vir Biotechnology, Inc.

2023-Q2 EPS reported -$2.51 revenue$66,754,000

Net loss $194.8M ($1.45/sh) vs $76.5M loss YoY; revenues $3.8M (incl $16.5M grant).
Cash $1.9B at June 30; $273.6M paid to GSK for excess sotrovimab supply.
Discontinued innate immunity small molecule platform to focus on antibody platform.
Phase 2 PENINSULA flu trial (VIR-2482) missed primary and secondary endpoints.
Phase 2 hep B/delta data (VIR-2218/VIR-3434) expected Q4 2023; HIV vaccine VIR-1388 Phase 1 dosing expected Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.